Physician profile
Peter Berkey
NPI 1881761245
$10,095.96
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,805 · 2020: $552 · 2021: $135 · 2022: $4,582 · 2023: $690 · 2024: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $5,422.33 | 2019-2024 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $3,399.87 | 2019-2024 | |
| Theratechnologies INC. | $443.28 | 2019-2023 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $282.55 | 2019-2024 | Pifeltro, Delstrigo |
| Abbvie INC. | $197.90 | 2019-2024 | Mavyret |
| Janssen Products, Lp | $179.22 | 2019-2021 | |
| Janssen Biotech, INC. | $70.62 | 2019 | |
| Emd Serono, INC. | $28.94 | 2019 | |
| Hologic Sales and Service, LLC | $25.24 | 2024 | Thinprep 2000 Processor, Aptima |
| Glaxosmithkline, LLC. | $23.39 | 2023 | Shingrix, Arexvy |
| Napo Pharmaceuticals INC | $22.62 | 2023 | Mytesi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Berkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.